Editorial Article

AI in Pharmacy Sells at a Falling Price. That Is the Business Model.

Updated November 18, 2026

The pitch for artificial intelligence in pharmacy is almost always a premium story. Better verification, fewer errors, more clinical time — and a price to match. The arithmetic of the market says something different, and it is worth stating plainly because it determines who wins.

The AI in pharmacy market is USD 1,840 million in 2025 and reaches USD 7,310 million by 2033. That is 18.82 per cent a year, which sounds like a premium market. But the site count behind it rises from 52,000 to 396,000 over the same eight years — 28.89 per cent a year — while revenue per AI-enabled site falls from USD 35,385 to USD 18,460, or 7.81 per cent annually. Nine points of penetration produce seven and a half points of value, because a fifth of the price disappears every three years.

Strip the headline growth rate away and what remains is a market doubling its reach roughly every three years while surrendering its pricing over the same interval. That is not a premium category. It is a commodity finding a mass market, and it is happening faster in pharmacy than in most of healthcare because pharmacy is where the labour arithmetic is most brutal and most measurable.

The equipment next door does the opposite

The comparison that settles the argument sits in the same segment of the same website. The pharmacy automation system market grows 7.76 per cent a year — less than half the rate — but it does so on 4.90 per cent unit growth and a 2.73 per cent rise in revenue per system. Automation asks for more money per installation each year. Software asks for less per site.

The reason is physical rather than strategic. A dispensing configuration at a central-fill site genuinely gets bigger each generation: more cells, more robotics, more integration, more service. The average selling price appreciates because the object appreciates. A model call does not appreciate. The cost of running the same verification task falls every year, and a buyer on a multi-year contract now treats that decline as something to be negotiated rather than something to be grateful for.

Which means the two markets are not really two markets. They are one budget, and the money is made on the equipment while the margin migrates to whatever sits next to it.

Why the price falls so reliably

Three mechanisms, and only the first is technological.

The first is inference cost. Whatever a verification model costs to run in 2026, it costs materially less in 2029, and buyers have learned to write that expectation into contracts.

The second is how the product is sold. Across our vendor interviews, AI in pharmacy almost never appeared as its own line item. It appeared as a percentage uplift on an automation bid — typically mid single digits to low teens of contract value. Once intelligence is priced as a percentage of something else, it inherits the negotiation that governs that something else. It becomes the discount the buyer asks for at the end, not the capability the buyer came for at the beginning.

The third is the estate. The National Community Pharmacists Association counted 18,960 independent community pharmacy locations in July 2025, down from 18,984 a year earlier, with independents representing nearly 36 per cent of all US retail pharmacies. That puts the total US retail estate in the region of 52,700 locations, and the direction is one way. When the number of places you can sell into is shrinking, you buy reach with price.

And yet demand is the least uncertain thing in the market

Here is the part that makes the deflation a commercial problem rather than a demand problem. The labour case for pharmacy AI is documented with a precision the market sizing can only envy.

The American Society of Health-System Pharmacists surveyed hospital pharmacy directors in autumn 2024 and found 56.2 per cent of hospitals reporting shortages in pharmacy leadership roles — while pharmacist clinical deployment expanded sharply over the preceding decade. Emergency department involvement rose from 10.9 per cent ten years earlier to 46.5 per cent. Critical care reached 68.5 per cent, oncology 56.9 per cent, infectious disease and antimicrobial stewardship 48.1 per cent.

Read those two facts together. Hospitals are deploying pharmacists into more clinical settings while struggling to fill the leadership roles that would organise that deployment. Every hour a pharmacist spends on a verification queue is an hour not spent on the work the survey says hospitals want pharmacists doing. That is as clean a demand signal as healthcare produces.

On the administrative side the figure is even sharper. CMS estimates that requesting prior authorisations costs providers USD 20–50 per hour and consumes 13 hours a week — roughly USD 34,000 and 700 hours of administrative time per provider per year. That is a document-understanding problem, not a clinical one, which is exactly why it is the application spreading fastest despite attracting the least attention.

So the market has a demand curve that is close to certain and a price curve that falls every year. Most categories face the opposite problem.

What a vendor is supposed to do about it

Omnicell’s 2025 is the clearest available answer. The company reported fiscal 2025 total revenues of USD 1.185 billion, up 7 per cent, attributed to strength in connected devices, technical services, and SaaS and Expert Services. It used the ASHP 2025 Midyear Clinical Meeting to launch Titan XT as a step toward autonomous medication management, extending beyond the pharmacy into nursing care areas.

That is a reply to deflation rather than a denial of it. If revenue per site falls, the response is not to charge more for intelligence — the market will not bear it. The response is to increase the number of things per site that carry a recurring charge, and to move toward the care-area endpoint where the remaining manual labour actually sits. Intelligence becomes the reason to renew the equipment contract, not the product in its own right.

A software-only vendor has no such lever. It can match the price of intelligence but cannot recover it elsewhere, and it cannot fund site-specific validation documentation out of a licence that is shrinking. That is the structural reason two of this market’s three cohorts — distributors embedding AI in logistics, and software-native vendors selling modules — are in a weaker position than the equipment incumbents, regardless of whose model performs better.

The one number that decides the decade

Our forecast is most fragile not to the site count but to the price. If revenue per site held flat at USD 35,385 while the site count still reached 396,000, the 2033 market would be about USD 14,012 million — nearly double our figure. The difference between those two worlds is not adoption. It is whether AI in pharmacy ever becomes something a buyer will pay more for over time.

The contracts say no. Intelligence is being absorbed into equipment and workflow budgets rather than established beside them, and absorbed things are priced by the thing absorbing them. That is good news for how much will be deployed and bad news for what it will be sold for — and it is why the commercial value in this cluster belongs to whoever already owns the workflow when the intelligence arrives.

Read the full analysis in Global Artificial Intelligence in Pharmacy Market Report, Size, Share and Forecast 2026–2033. Sources: Omnicell fiscal year 2025 results; ASHP national survey, American Journal of Health-System Pharmacy; NCPA 2025 Digest; CMS electronic prior authorisation programme; Pheonix Research modelling.

Frequently Asked Questions

Is the AI in pharmacy market actually growing?

Yes, at 18.82 per cent a year, from USD 1,840 million in 2025 to USD 7,310 million by 2033. What is shrinking is the price: revenue per AI-enabled site falls from USD 35,385 to USD 18,460, or 7.81 per cent annually.

Why does AI in pharmacy deflate when pharmacy automation does not?

Because the object being sold behaves differently. A dispensing configuration gets physically larger each generation, so its average selling price appreciates — automation grows on 4.90 per cent unit growth and a 2.73 per cent rise in revenue per system. A model call gets cheaper, and buyers negotiate that decline instead of ignoring it.

What happens if revenue per site does not fall?

The 2033 market would be approximately USD 14,012 million rather than USD 7,310 million. The single most consequential assumption in the forecast is the deflation rate, not the adoption rate.

Who benefits from a deflating price?

Whoever already owns the workflow. Equipment incumbents can bundle intelligence into an automation contract and recover margin on hardware and service; standalone software vendors must fund site-specific validation out of a licence that shrinks every year.